80 GUEST STREET, BOSTON, MA
Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Bringing Transformative Oncology Therapies to Patients Corporate Presentation I July 2026
Compass Therapeutics Adopts Second Amended and Restated Bylaws
Stockholders Elect Directors at Compass Therapeutics Annual Meeting
Reports 2026 First Quarter Financial Results and Provides Corporate Update
Annual Report to Security Holders
Corporate Presentation Nasdaq: CMPX April 27, 2026
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Amended Statement of Changes in Beneficial Ownership
Delisting Amendment